|
|
|
Volumn 6, Issue 2, 2007, Pages 137-
|
|
Gemcitabine plus bevacizumab no better than gemcitabine alone in clinical study of 600 patients with pancreatic cancer.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
ANTINEOPLASTIC AGENT;
ANTINEOPLASTIC ANTIMETABOLITE;
BEVACIZUMAB;
DEOXYCYTIDINE;
DRUG DERIVATIVE;
GEMCITABINE;
MONOCLONAL ANTIBODY;
ARTICLE;
CLINICAL TRIAL;
FEMALE;
HUMAN;
MALE;
PANCREAS TUMOR;
TREATMENT OUTCOME;
ANGIOGENESIS INHIBITORS;
ANTIBODIES, MONOCLONAL;
ANTIMETABOLITES, ANTINEOPLASTIC;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CLINICAL TRIALS;
DEOXYCYTIDINE;
FEMALE;
HUMANS;
MALE;
PANCREATIC NEOPLASMS;
TREATMENT OUTCOME;
|
|
EID: 34548439322
PISSN: 15384047
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (11)
|
|
References (0)
|